$1 billion to help develop Parkinson's disease therapy, and Yan Jian and Denali have reached a partnership.

Parkinson's disease is the second most common neurodegenerative disease, with symptoms including tremors, slow movement, muscle stiffness and impaired balance.
as these symptoms get worse, patients have difficulty walking, talking, or performing other simple tasks.
LRRK2 is a regulatory factor in lysozymatic function, and in Parkinson's disease, LRRK2 function is abnormal, which may lead to neurodegenerative lesions.
Denali's research suggests that inhibiting LRRK2 activity may be effective not only in patients with Parkinson's disease who carry the LRRK2 gene mutation, but also in patients who do not carry the LRRK2 gene mutation by restoring the function of the lysosome.
agreement, Yan Jian will work with Denali in the United States and China to develop and commercialize Denali's LRRK2 small molecule inhibitors for the treatment of Parkinson's disease.
will be responsible for the commercialization of all other markets.
DNL151 completed administration of 162 healthy volunteers in an ongoing Phase 1 clinical study, and 25 Parkinson's patients in a Phase 1b clinical study.
Denali is currently completing a further dose-increasing queue in an extended phase 1 study and another queue in the phase 1b study to determine the complete treatment window for the molecule.
will make an upfront payment of $560 million to Denali and a $465 million equity investment in Denali.
Denali is also eligible for potential milestone payments of up to $1,125 million.
References: (BIOGEN AND DENALI) TO COLLABORATE ON LRRK2 PROGRAM FOR PARKINSON'S DISEASE AND MADE TV PLATFORM-ENABLEDS FOR NEURODEGENERATIVE DISEASES. Retrieved August 6, 2020, from.